高级检索
    何艳, 钱朝霞, 方陈, 陈永, 吴龙云. 噻托溴铵吸入剂治疗稳定期D组慢性阻塞性肺疾病疗效分析[J]. 蚌埠医科大学学报, 2020, 45(4): 489-492. DOI: 10.13898/j.cnki.issn.1000-2200.2020.04.018
    引用本文: 何艳, 钱朝霞, 方陈, 陈永, 吴龙云. 噻托溴铵吸入剂治疗稳定期D组慢性阻塞性肺疾病疗效分析[J]. 蚌埠医科大学学报, 2020, 45(4): 489-492. DOI: 10.13898/j.cnki.issn.1000-2200.2020.04.018
    shu
    HE Yan, QIAN Zhao-xia, FANG Chen, CHEN Yong, WU Long-yun. Efficacy analysis of tiotropium bromide inhalant in the treatment of COPD in stable period D group[J]. Journal of Bengbu Medical University, 2020, 45(4): 489-492. DOI: 10.13898/j.cnki.issn.1000-2200.2020.04.018
    Citation: HE Yan, QIAN Zhao-xia, FANG Chen, CHEN Yong, WU Long-yun. Efficacy analysis of tiotropium bromide inhalant in the treatment of COPD in stable period D group[J]. Journal of Bengbu Medical University, 2020, 45(4): 489-492. DOI: 10.13898/j.cnki.issn.1000-2200.2020.04.018
    shu

    噻托溴铵吸入剂治疗稳定期D组慢性阻塞性肺疾病疗效分析

    Efficacy analysis of tiotropium bromide inhalant in the treatment of COPD in stable period D group

      摘要
    • 摘要:
      目的探讨噻托溴铵吸入剂对稳定期D组慢性阻塞性肺疾病（COPD）病人临床症状、肺功能及其生活质量的改善作用。
      方法选取92例稳定期D组（按GOLD 2018分组）COPD病人为研究对象，依据随机数字表法分为观察组（n=46）和对照组（n=46）。对照组行肺功能锻炼及布地奈德/福莫特罗吸入治疗，观察组在对照组基础上联合噻托溴铵吸入剂治疗，治疗6个月后比较2组病人6 min步行距离（6MWD）、肺功能（FEV1、FVC）、临床症状评分（CAT）、呼吸困难程度（mMRC评分）、生活质量（SGRQ评分）。
      结果2组病人FEV1、FVC治疗后较治疗前均改善，观察组高于对照组（P < 0.01）；2组6MWD均较治疗前改善，且观察组高于对照组（P < 0.01）；治疗后2组病人CAT、mMRC、SCRQ评分均减少，观察组改善优于对照组（P < 0.01）。
      结论肺功能锻炼联合噻托溴铵及布地奈德/福莫特罗治疗稳定期D组COPD病人能有效改善病人的临床症状及肺功能，提高病人的生活质量。

       

      Abstract:
      ObjectiveTo investigate the effects of tiotropium bromide inhalant on clinical symptoms, pulmonary function and quality of life in patients with chronic obstructive pulmonary disease(COPD) in stable group D.
      MethodsNinety-two patients with stable COPD in group D(according to GOLD 2018) were randomly divided into the observation group(n=46) and control group(n=46).The control group was treated with function exercise and budesonide/formoterol inhalation, and the observation group was treated with tiotropium bromide inhalant on the basis of the control group.After six months of treatment, the lung function(FEV1 and FVC), six-minute walking distance(6MWD), clinical symptom score(CAT), dyspnea degree(mMRC score), quality of life(SGRQ score) were compared between two groups.
      ResultsAfter treatment, the FEV1 and FVC in two groups were improved compared with those before treatment, and the FEV1 and FVC in observation group were higher than those in control group(P < 0.01).After treatment, the 6MWD in two groups was improved compared with that before treatment, and the 6MWD in observation group was higher than that in control group(P < 0.01).After treatment, the scores of the CAT, mMRC and SGRQ reduced, and the improvement degree in observation group was better than that in control group(P < 0.01).
      ConclusionsTiotropium bromide inhalant combined with pulmonary function exercise and budesonide/formoterol in treating the stable COPD in group D can effectively improve the symptoms, pulmonary function and quality of life of patients.

       

      • HTML全文
      • 参考文献(13)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回